ABBV-2294
Stories
-
AbbVie registers Phase 2b/3 study of ABBV-2294 in systemic sclerosis
The study plans to enroll 580 participants at about 200 sites worldwide, with a planned start date of December 11, 2026. It plans to evaluate the safety and efficacy of the combination of ABBV-722 and upadacitinib versus placebo over 52 weeks with optional extension periods.